Clinically, von Willebrand disease (VWD) presents as mucosal bleeding caused by a decreased quantity or quality of von Willebrand factor (VWF). Diagnosis of VWD requires careful consideration of patient specific factors, bleeding symptoms, and laboratory results. Patients with borderline low VWF levels remain challenging, given that low VWF is not necessarily a guarantee of bleeding, but is present in many patients with symptoms, and treatment of low VWF may improve bleeding. Laboratory diagnosis of VWD is complex and no single test can determine the presence or absence of functional VWF. Historically, VWF binding to platelet GPIbα was measured by the ristocetin cofactor assay (VWF:RCo); a new assay using platelet GPIbα in the absence of ristocetin (VWF:GPIbM) is gradually replacing the VWF:RCo due to improved accuracy in diagnosis. VWF binding to collagen is a separate function, and requires specific testing to determine if a collagen binding defect is present. Regardless of these laboratory complexities, clinicians can empirically treat VWD to alleviate bleeding symptoms by raising VWF levels through desmopressin or VWF concentrate.
von Willebrand disease (VWD) is thought to be the most common bleeding disorder, affecting up to 0.1% of the population. 1 Patients with VWD typically present with mild to severe mucosal bleeding including epistaxis, menorrhagia, gingival bleeding, bruising, and gastrointestinal bleeding. Personal and family history of bleeding, along with appropriate laboratory findings, is sufficient to make a diagnosis of VWD. 2 Laboratory testing for VWD is complex and physicians do not consistently perform the same battery of tests on all patients.
The purpose of this article is to provide an overview and discussion of some issues around the diagnosis of VWD.
| CLASSIFICATION OF VON WILLEBRAND DISEASE
VWD is classified into three major types: type 1 VWD, type 2 VWD, and type 3 VWD. Within these three types there are two kinds of pathophysiology, those due to decreased quantity of VWF and those due to decreased quality of VWF. A specific type 1 VWD subgroup includes those with increased clearance of VWF, also called type 1C VWD. 4 Type 1 VWD patients have a decreased VWF antigen (VWF:Ag), decreased ability of VWF to bind platelets (measured by either decreased binding to platelet GPIb through the VWF:GPIbM assay or decreased ristocetininduced binding to platelets by the ristocetin cofactor activity assay), and decreased ability to bind collagen (VWF:CB). The VWF propeptide will be elevated in type 1C. 5 However, activity to antigen ratios will be normal since the VWF protein produced still maintains normal function.
With regard to type 3 VWD, some have used this category to include those with minimal residual VWF levels (ie, <5 IU/dL). 6 Others consider any detectable VWF to represent type 1 VWD, albeit a more severe phenotype, and reserve the label of type 3 VWD for those with completely undetectable VWF levels. 2, 7 The distinction is relevant to the inheritance, as type 1 is considered to be autosomal dominant and type 3 autosomal recessive, but not to treatment, as any patient with VWF levels <10 IU/dL will likely require treatment with a VWF concentrate. This discussion will be echoed below under "treatment of VWD" but there is a divergence between biologists whose interest is the pathophysiology of the disease and clinicians whose main concern remains the required treatment.
Type 2 VWD is classified as a decreased function of VWF, where
VWF does not perform one or more of its native functions properly.
Type 2 VWD is further divided into sub-types: 2A, 2B, 2M, and 2N.
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The dysfunctions in type 2 VWD can be a loss of function, as seen in
The structure of VWF. The D1 and D2 domains make up the VWF propeptide and are cleaved in the production of mature VWF. The D′ and D3 domains bind factor VIII (FVIII), the A1 domain binds platelets (PLT) and collagen (COL), and the A3 domain also binds collagen. VWF, von Willebrand factor Figure 2C ).
Type 2A VWD is inherited as an autosomal dominant trait and accounts for 10-20% of VWD cases. 7 Mutations in the A2 domain, N terminal D3 domain, and C terminus (see Figure 2A) figure 2A . 11 The pathogenic change in the A1 domain in type 2B VWD causes VWF to more readily bind platelets, 
acting as a gain of function mutation, and resulting in increased uptake and destruction of the VWF-platelet complex. 12 In some cases the destruction of platelets in type 2B VWD can cause thrombocytopenia. 13 The sequestration of the VWF-platelet complexes also results in a loss of HMWM. These patients will have a decreased VWF:Ag, a low VWF:GPIbM/VWF:Ag ratio, a low VWF:CB/VWF:Ag ratio, an absence of HMWM, and an increased VWF:PB or an increased LD-RIPA. Figure 2D , between p.S764 and p.R1035, which contain the binding site for FVIII. 9 Without the proper protection afforded by VWF, FVIII is degraded in plasma. These patients may have a normal VWF:Ag with a normal distribution of multimers, but will have a low FVIII activity to VWF antigen ratio (FVIII:C/VWF:Ag), and low FVIII binding (VWF:FVIIIB). Because VWF levels may be normal, type 2N VWD is sometimes misdiagnosed as hemophilia A. 19 A primary concern for clinicians is to ensure patients are not incorrectly diagnosed with mild hemophilia, and treated with only FVIII, which will not suffice to improve bleeding symptoms.
| DIAGNOSIS OF VWD
Suspicion of VWD starts with a bleeding phenotype. Bleeding assessment tools (BATs) are questionnaires used to help clinicians evaluate a patient's history of bleeding symptoms and assign them a score based on the severity of those bleeding symptoms. BATs objectively score patients based on the severity, duration, and need for treatment for bleeding episodes. The International Society of Thrombosis and Hemostasis (ISTH) has created a comprehensive questionnaire (ISTH-BAT) that can be used by researchers and clinicians. 20 The normal score on the ISTH-BAT is 0-3 for adult males, 0-5 for adult females, and 0-2 for children. A positive or abnormal score would be ≥4 for males, ≥6 for females, and ≥3 for children, all of which should be considered further for bleeding disorders, including VWD.
21
Bleeding assessment, either clinically or using a bleeding assessment tool, is critical when considering a diagnosis of VWD as some patients may have low VWF levels but lack bleeding symptoms and likely should not receive a diagnosis of VWD. 24 There may be a genetic reason for this, as the incidence of sequence variants in VWF increase with decreasing VWF:Ag, and there does appear to be a significant increase in frequency of such variants with VWF levels below 30 IU/dL.
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However, one confounder of many of the current studies is the predilection for inclusion of subjects with a pre-existing diagnosis of VWD.
In general, such subjects are diagnosed because of bleeding, and typically once a diagnosis of VWD is reached, clinicians stop their evaluation. Thus, some cases may have concomitant platelet defects or other coagulation defects that also contribute to bleeding.
The case for additional genetic modifiers of VWF is also growing stronger. While ABO blood group is the only modifier with substantial evidence in patients, 23 several publications have implicated other genes in VWF pathophysiology including CLEC4M and STXBP5. 28, 29 This raises the question of whether VWD is exclusively the province of variants in VWF, or the sum of all factors affecting VWF and coagulation in a given individual. 
| RISE OF THE VWF:GPIBM ASSAY (AND DEATH OF THE VWF:RCO?)
Previously VWF function was measured using the ristocetin cofactor activity assay (VWF:RCo). 33 However, VWF:RCo has poor reproducibility between laboratories, giving a wide range of results and interpretations. 34, 35 Additional platelet-dependent VWF activity assays include using a monoclonal antibody to detect the GPIb site of VWF (VWF:Ab), and using a recombinant GPIb to induce ristocetin binding to VWF (VWF:GPIbR). The VWF:Ab assay does not necessarily test the function of the GPIb domain, rather the presence of it, but is an option in many laboratories. 36 The VWF:GPIbR still requires optimal ristocetin concentration, and is therefore subject to some of the same limitations as the VWF:RCo, but may have improved coefficient of variation. 37 Since testing the platelet binding ability of VWF is crucial to understanding VWF function and differentiating between quantitative or qualitative defects in VWF, high levels of variability have been a burden on clinicians in the process of diagnosing VWD. The inconsistencies and inadequacies in these assays, and the potential for misdiagnosis, have led to the novel VWF:GPIbM assay.
The VWF:GPIbM assay exploits of gain of function variants in the platelet GPIbα domain that accomplishes the same purpose as the ristocetin cofactor assay: measuring VWF's ability to bind platelets, but without the requirement for ristocetin. 38 The name VWF:GPIbM refers to the use of GPIb rather than platelets and to the fact that the GPIb contains mutations (M) as per ISTH recommendations for VWF activity assay nomenclature. 39 To properly evaluate VWF:GPIbM, results should be considered in context of VWF:Ag. If there is a discrepancy between VWF:Ag and VWF:GPIbM (ie, VWF:Ag is low and VWF:GPIbM is much lower), concern is raised for a qualitative dysfunction in VWF.
| CLINICAL EVALUATION OF VWF COLLAGEN BINDING
Collagen binding (VWF:CB) can be tested via ELISA and measures one of the major functions of VWF. VWF:CB should be considered in pro- Human type I and type III collagens are most commonly used in testing VWF:CB because of their sensitivity and specificity. 40 Collagens I and III bind to the A3 domain of VWF. 41 The VWF:CB assay can be have also been shown to abrogate VWF binding to collagen IV. 44, 46 If a defect in VWF function is suspected due to increased bleeding, evaluation of VWF binding to platelets and collagen types I and III may not suffice.
| TREATMENT OF VWD
The classification and diagnosis of VWD is complicated. As a biologist, the classification and laboratory differentiation of VWD is something that may be of significant interest and should be explored more thoroughly. However, as a clinician the important conclusion that needs to be reached is how to treat the patient. Figure 3 depicts a flowchart outlining possible treatment paths for patients depending on VWF laboratory assay results, with the understanding that such testing is being performed on a symptomatic patient.
If a patient is experiencing bleeding symptoms and has a decreased VWF level, empiric treatment can be provided to raise VWF levels. 
